Nu Skin Enterprises Reports Second Quarter Results
NU SKIN ENTERPRISES, INC. (NUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Nu Skin Enterprises Reports Second Quarter Results PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results. Executive Summary Q2 2026 vs. Prior-year Quarter Revenue $320.1 million; (17.1)% • (1.0
How this was made
The 30-second read
Why it matters
The actionable items are the reported Q2 financials and the updated FY 2026 revenue and adjusted EPS guidance ranges, which can prompt immediate changes to earnings models and near-term positioning.
Market read
Guidance update plus quarterly results are likely to be the primary driver for short-term trading, especially given year-over-year revenue decline and the magnitude of reported EPS loss versus adjusted profitability.
What to watch
The release emphasizes non-cash impairment and non-cash tax charges, plus FX impact ranges. Traders should separate underlying operating margin trends from accounting charges and scrutinize the implied FX sensitivity in the guidance.
Nu Skin Enterprises Reports Second Quarter Results
Revenue declined 17.1% year over year, every reported operating segment declined, customer and sales-force metrics fell, and GAAP EPS was $(5.14) amid non-cash impairment and tax charges.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $320.1M | – | (17.1)% |
| Revenue constant-currency changenon-GAAP | (16.1)% | – | (16.1)% |
| Foreign-exchange impact on revenuenon-GAAP | (1.0)% FX impact or $(4.0) million | – | – |
| Gross MarginGAAP | 68.2% | – | – |
| Nu Skin business gross marginother | 77.7% | – | – |
| Selling ExpensesGAAP | 33.7% | – | – |
| Nu Skin business selling expensesother | 39.8% | – | – |
| G&A ExpensesGAAP | 28.4% | – | – |
| Operating MarginGAAP | (18.5)% | – | – |
| Operating Margin excluding non-cash impairment chargenon-GAAP | 6.1% | – | – |
| Interest ExpenseGAAP | $3.3M | – | – |
| Other Income (Expense)GAAP | −$500K | – | – |
| Income Tax RateGAAP | (295.4)% | – | – |
| Income Tax Rate excluding non-cash tax chargenon-GAAP | 36.6% | – | – |
| EPSGAAP | $(5.14) | – | – |
| EPS excluding non-cash impairment and non-cash tax chargesnon-GAAP | $0.20 | – | – |
| Customersother | 660,037 | – | (14)% |
| Paid Affiliatesother | 120,291 | – | (8)% |
| Sales Leadersother | 26,998 | – | (9)% |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Nu Skin AmericasConstant-currency change was (15.8)%. | $59.76M | – | (18.1)% |
| Mainland ChinaConstant-currency change was (18.7)%. | $45.96M | – | (13.7)% |
| Southeast Asia/PacificConstant-currency change was (16.3)%. | $43.26M | – | (14.9)% |
| JapanConstant-currency change was (5.5)%. | $38.14M | – | (14.4)% |
| Europe & AfricaConstant-currency change was (15.2)%. | $32.32M | – | (13.4)% |
| Hong Kong/TaiwanConstant-currency change was (3.6)%. | $26.07M | – | (5.3)% |
| South KoreaConstant-currency change was (19.0)%. | $25.62M | – | (24.8)% |
| Nu Skin OtherConstant-currency change was (81.5)%. | $79 | – | (81.5)% |
| Total Nu SkinConstant-currency change was (14.2)%. | $271.2M | – | (15.5)% |
| Rhyz ManufacturingConstant-currency change was (23.2)%. | $46.37M | – | (23.2)% |
| Rhyz OtherConstant-currency change was (47.6)%. | $2.53M | – | (47.6)% |
| Total RhyzConstant-currency change was (25.0)%. | $48.90M | – | (25.0)% |
| TotalConstant-currency change was (16.1)%. | $320.1M | – | (17.1)% |
Q3 2026 and Full-year 2026 outlook
- RevenueQ3 2026 Revenue $310 to $340 million; (15)% to (7)%. 2026 Revenue $1.28 to $1.35 billion; (14)% to (9)%.
- NoteQ3 2026 EPS $0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
- NoteQ3 2026: Approximately (3) to (2)% FX impact
- Note2026 EPS ($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis
- Note2026: Approximately (1)% FX impact
Capital returns
- Dividend Payments $2.9 million
- Stock Repurchases $0.0 million
- $137.3 million remaining in authorization
What drove it
- The company cited continued rollout of Prysm iO and preparations for the formal launch of India.
- Management said it is re-aligning organizational resources to better position the business to drive sustainable, long-term value for shareholders.
- Adjusted EPS reflected an ongoing focus on profitability and disciplined execution.
Concerns
- Total revenue declined (17.1)% year over year, including a (16.1)% constant-currency decline.
- All reported Nu Skin geographic segments and both reported Rhyz categories recorded year-over-year revenue declines.
- Customers declined (14)%, Paid Affiliates declined (8)%, and Sales Leaders declined (9)%.
- GAAP operating margin was (18.5)% and GAAP EPS was $(5.14), reflecting non-cash impairment and non-cash tax charges.
- Gross margin declined to 68.2% from 68.8%, while selling expenses and G&A expenses increased as percentages of revenue.
What to watch
- Q3 2026 revenue guidance of $310 to $340 million and adjusted EPS guidance of $0.10 to $0.20.
- Full-year 2026 revenue guidance of $1.28 to $1.35 billion and adjusted EPS guidance of $0.70 to $0.90.
- The continued rollout of Prysm iO and preparations for the formal launch of India.
- Customer, Paid Affiliate, and Sales Leader trends.
- Progress in restoring GAAP profitability following the second-quarter non-cash impairment and tax charges.
Analysis
Nu Skin reported a weak second quarter, with revenue of $320.1 million, down (17.1)% from $386.1 million. Currency accounted for a (1.0)% impact, while the reported constant-currency revenue change was (16.1)%. The underlying decline was broad: Total Nu Skin revenue fell (15.5)% and Total Rhyz revenue fell (25.0)%, while all reported geographic and Rhyz categories posted lower revenue year over year.
Sales-force and customer indicators also moved lower. Customers were 660,037, down (14)%, Paid Affiliates were 120,291, down (8)%, and Sales Leaders were 26,998, down (9)%. South Korea had the steepest reported geographic revenue decline at (24.8)%, while Rhyz Manufacturing declined (23.2)% and Rhyz Other declined (47.6)%. Hong Kong/Taiwan was the least negative reported geographic market, with revenue down (5.3)%.
Margin performance was pressured on a GAAP basis. Gross margin declined to 68.2% from 68.8%, selling expenses increased to 33.7% from 33.2%, and G&A expenses increased to 28.4% from 27.6%. GAAP operating margin was (18.5)%, while operating margin excluding the non-cash impairment charge was 6.1%. The company reported GAAP EPS of $(5.14), versus $0.43, while EPS excluding non-cash impairment and non-cash tax charges was $0.20. The GAAP income tax rate was (295.4)%, compared with 23.0%, and was 36.6% excluding the non-cash tax charge.
Capital returns were limited to $2.9 million of dividend payments, with $0.0 million of stock repurchases. The company reported $137.3 million remaining in its repurchase authorization. Management emphasized the Prysm iO rollout, preparations for India, and organizational resource realignment, positioning these actions as components of its long-term strategy.
For Q3 2026, Nu Skin guided revenue to $310 to $340 million, with a (15)% to (7)% year-over-year change and approximately (3) to (2)% FX impact. It guided GAAP EPS to $0.00 to $0.09 and adjusted EPS to $0.10 to $0.20. For 2026, the company guided revenue to $1.28 to $1.35 billion, a (14)% to (9)% change, and GAAP EPS to ($4.90) to ($4.73), or adjusted EPS of $0.70 to $0.90. The release states that annual guidance was updated, but no previous outlook was provided for comparison.
Management, verbatim
We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India.
Ryan Napierski, Nu Skin president and CEO
At the same time, we are re-aligning our organizational resources to better position the business to drive sustainable, long-term value for our shareholders.
Ryan Napierski, Nu Skin president and CEO
We delivered adjusted earnings per share near the midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution.
Chelsea Lantz, interim chief financial officer
Not in the filing
stated, not guessed- GAAP operating income
- Non-GAAP operating income
- GAAP net income
- Non-GAAP net income
- Operating cash flow
- Free cash flow
- Cash and cash equivalents
- Debt
- Capital expenditures
- Detailed impairment charge amount
- Detailed non-cash tax charge amount
- Prior-quarter revenue, margins, expenses, earnings, EPS, customer, affiliate, and Sales Leader metrics
- Forward guidance for gross margin
- Forward guidance for operating expenses
- Forward guidance for tax rate
- Previous-quarter outlook for comparison with reported results
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K with Exhibit 99.1 reporting Nu Skin’s Q2 2026 results and providing Q3 and full-year 2026 outlook, including commentary on Prysm iO rollout and preparations for a formal India launch.
Ticker impact
Nu Skin reports Q2 revenue of $320.1M and updates FY 2026 guidance to $1.28B-$1.35B revenue with adjusted EPS $0.70-$0.90.
Likely downside bias on open if investors focus on the large reported EPS loss and weaker revenue trend, partially offset by adjusted EPS guidance.
Reported EPS is $(5.14) with a stated adjusted EPS of $0.20, while revenue declines year over year and FY adjusted EPS is guided to $0.70-$0.90. The guidance update is the key tradable catalyst, but the magnitude of the market reaction depends on how investors weigh adjusted vs non-cash items and FX assumptions.
Market effects
Direct-selling and beauty/wellness peers may see read-across on affiliate demand, device platform rollout (Prysm iO), and FX sensitivity.
India launch preparations and Mainland China regulatory/scrutiny risk are highlighted, which can influence regional sentiment for similar direct-selling models.
FX impact assumptions and global demand conditions are explicitly referenced, which can affect broader consumer discretionary and international growth sentiment.
Counterpoint
Investors may look past the reported EPS loss and focus on adjusted EPS delivery near the midpoint of guidance, treating the guidance update as a controlled reset rather than deterioration.
Key entities
- companyNu Skin Enterprises, Inc.
Reports Q2 2026 results and updates Q3 and FY 2026 guidance, citing Prysm iO rollout and India launch preparations.
- product_platformPrysm iO
Nu Skin’s intelligent wellness platform referenced as being rolled out during the quarter.
- initiativeIndia launch
Company states it is preparing for a formal launch in India.
